These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 17055257)
1. What do we know about the mechanisms of aromatase inhibitor resistance? Chen S; Masri S; Wang X; Phung S; Yuan YC; Wu X J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):232-40. PubMed ID: 17055257 [TBL] [Abstract][Full Text] [Related]
2. New experimental models for aromatase inhibitor resistance. Chen S; Masri S; Hong Y; Wang X; Phung S; Yuan YC; Wu X J Steroid Biochem Mol Biol; 2007; 106(1-5):8-15. PubMed ID: 17611102 [TBL] [Abstract][Full Text] [Related]
3. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755 [TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. Masri S; Phung S; Wang X; Chen S J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035 [TBL] [Abstract][Full Text] [Related]
5. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049 [TBL] [Abstract][Full Text] [Related]
7. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy. Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878 [TBL] [Abstract][Full Text] [Related]
8. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. Wong C; Chen S J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):83-92. PubMed ID: 22265958 [TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells. Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887 [TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. Kijima I; Itoh T; Chen S J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272 [TBL] [Abstract][Full Text] [Related]
12. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Wong C; Wang X; Smith D; Reddy K; Chen S Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627 [TBL] [Abstract][Full Text] [Related]
13. Aromatase and breast cancer. Brodie A; Sabnis G; Jelovac D J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978 [TBL] [Abstract][Full Text] [Related]
14. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications. Hanamura T; Hayashi SI Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808 [TBL] [Abstract][Full Text] [Related]
15. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578 [TBL] [Abstract][Full Text] [Related]
16. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Berry J Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441 [TBL] [Abstract][Full Text] [Related]
17. An "omics" approach to determine the mechanisms of acquired aromatase inhibitor resistance. Chen S OMICS; 2011 Jun; 15(6):347-52. PubMed ID: 21332390 [TBL] [Abstract][Full Text] [Related]
18. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells. Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197 [TBL] [Abstract][Full Text] [Related]
19. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Hole S; Pedersen AM; Lykkesfeldt AE; Yde CW Breast Cancer Res Treat; 2015 Feb; 149(3):715-26. PubMed ID: 25667100 [TBL] [Abstract][Full Text] [Related]
20. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]